KVP Capital Advisors, LP

SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$124.3M2026 Q3
Positions36
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.57.4%

KVP Capital Advisors, LP reported 36 positions worth $124.3M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: PRAX (10.1%). Biggest move: new buy SLN ($7.5M).

10 / 36 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PRAXPraxis Precision Medicines$12.5M10.05%42,900——+6.5%
▸ 2 WHWKWhitehawk Therapeutics$8.1M6.55%2,165,997———
▸ 3 SLNSilence Therapeutics$7.5M6.02%684,123———
▸ 4 PTGXProtagonist Therapeutics$7.5M6.01%53,000——-11.4%
▸ 5 MBXMBX Biosciences$7.1M5.73%121,524——-9.4%
▸ 6 ERASErasca$6.7M5.37%455,000———
▸ 7 TRVITrevi Therapeutics$5.9M4.77%414,000——-7.2%
▸ 8 TNGXTango Therapeutics$5.7M4.62%230,264——-3.1%
▸ 9 EWTXEdgewise Therapeutics$5.4M4.34%133,000——+7.6%
▸ 10 TNDMTandem Diabetes Care$4.9M3.95%301,000——+13.3%

Pro Feature

The remaining 26 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does KVP Capital Advisors, LP hold as of Q3 2026?

KVP Capital Advisors, LP reported 36 positions worth $124.3M in its Q3 2026 13F filing. Largest positions: PRAX (10.1%), WHWK (6.6%), SLN (6.0%), PTGX (6.0%) and MBX (5.7%).

What did KVP Capital Advisors, LP buy in Q3 2026?

New positions: SLN, VOGENX INC, ADIAL PHARMACEUTICALS INC and YARW.

What did KVP Capital Advisors, LP sell in Q3 2026?

Reduced: IRON. Sold out entirely: AXSM, SRRK and VYNE THERAPEUTICS INC.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.